- Stocks
- Pharma & Healthcare
- Concord Drugs
Concord Drugs share price
NSE: CONCORDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Concord Drugs at a glance
With a market capitalisation of ₹101 Cr, it ranks 2675th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 2.2% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹38 Cr (+264.7% year on year) and net profit ₹1 Cr (+1,225.0%), on a consolidated basis. Promoters held 45.08% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹101 CrRank 2675 on NSE
- Price to book
- 1.91×FY26
- EPS (TTM)
- ₹0.94to Q4 FY26
- ROE
- 2.2%FY26
- ROCE
- 5.9%FY26
- Debt to equity
- 0.28FY26
- Net profit margin
- 1.3%FY26
- Book value / share
- ₹36.82FY26
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Concord Drugs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹12 Cr | ₹12 Cr | ₹11 Cr | ₹10 Cr | ₹14 Cr | ₹10 Cr | ₹17 Cr | ₹38 Cr |
| Revenue YoY | +30.2% | +64.4% | −15.5% | −33.6% | +16.4% | −16.8% | +57.1% | +264.7% |
| Net profit | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Net profit YoY | −93.9% | −92.9% | — | — | +300.0% | +375.0% | −4.3% | +1,225.0% |
| Net margin | 0.3% | 0.3% | 2.1% | 0.4% | 0.9% | 1.8% | 1.3% | 1.4% |
| EPS | ₹0.03 | ₹0.04 | ₹0.23 | ₹0.04 | ₹0.12 | ₹0.19 | ₹0.16 | ₹0.47 |
Concord Drugs financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹52 Cr | ₹45 Cr | ₹45 Cr | — |
| Operating profit | ₹1 Cr | ₹1 Cr | ₹1 Cr | — |
| Net profit | ₹1 Cr | ₹0 Cr | ₹0 Cr | — |
| EPS (₹) | ₹1.00 | ₹0.00 | ₹0.00 | — |
| Cash from operations | ₹2 Cr | ₹1 Cr | ₹4 Cr | — |
| Total debt | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr |
| Shareholders' equity | ₹32 Cr | ₹34 Cr | ₹34 Cr | ₹49 Cr |
Concord Drugs shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 29 Nov 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 54.39% | 54.39% | 45.08% | 54.39% | 54.39% | 45.08% |
| Non-institutions | 45.61% | 45.61% | 54.92% | 45.61% | 45.61% | 54.92% |
Concord Drugs vs peers
The listed Pharma & Healthcare companies nearest to Concord Drugs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MERCURYLABMercury Labs | — | — | — | ₹102 Cr | — | — |
| VAISHALIVaishali Pharma | ₹7.49 | +2.04% | −30.3% | ₹101 Cr | 124.8 | — |
| CONCORDConcord Drugs | — | — | — | ₹101 Cr | — | — |
| DENISCHEMDenis Chem Lab | — | — | — | ₹101 Cr | — | — |
| FORTISMLRFortis Malar | — | — | — | ₹97 Cr | — | — |
| RAAJMEDIRaaj Medisafe | — | — | — | ₹97 Cr | — | — |
| KHFMKHFM HOSPITALIT | ₹40.90 | +4.87% | −50.1% | ₹95 Cr | — | — |
Ask anything about Concord Drugs
Pivot answers on the live chart with evidence you can check, and tests strategies against CONCORD's own history. Try: “Why has CONCORD moved over the last three months?” · “Backtest a 50-day moving-average crossover on CONCORD over five years” · “Compare CONCORD with MERCURYLAB on margins and valuation”
Frequently asked questions about Concord Drugs
What is the market cap of Concord Drugs?
Concord Drugs' market capitalisation is ₹101 Cr (₹101 Cr) at the 22 Oct 2026 close, ranking 2675th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Concord Drugs?
Return on equity was 2.2% in FY26 and return on capital employed was 5.9% in FY26 (consolidated figures).
Is Concord Drugs a debt-free company?
No. Concord Drugs' debt-to-equity ratio was 0.28 in FY26, with total debt of ₹2 Cr.
What were Concord Drugs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Concord Drugs reported revenue of ₹38 Cr, +264.7% year on year, and net profit of ₹1 Cr, +1,225.0% year on year.
What is the shareholding pattern of Concord Drugs?
As of 30 Jun 2026: promoters 45.08%, non-institutions 54.92%.
Who are Concord Drugs' competitors?
The listed Pharma & Healthcare companies closest to Concord Drugs by market cap are Mercury Labs, Vaishali Pharma, Denis Chem Lab, Fortis Malar, Raaj Medisafe and KHFM HOSPITALIT.
Is Concord Drugs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Concord Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CONCORD against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text